MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Phase 3

Completed

Conditions: Chronic Kidney Disease
Hyperphosphatemia
Dialysis

Interventions: Drug: MCI-196
Drug: Placebo

First Posted Date: 2007-07-25

Last Posted Date: 2014-09-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 245

Registration Number: NCT00506441

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: AST-120

First Posted Date: 2007-07-13

Last Posted Date: 2022-06-07

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 1015

Registration Number: NCT00501046

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: AST-120

First Posted Date: 2007-07-13

Last Posted Date: 2022-06-07

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 1020

Registration Number: NCT00500682

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: MCI-196
Drug: Placebo of MCI-196 Tablet

First Posted Date: 2007-07-06

Last Posted Date: 2012-06-08

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 183

Registration Number: NCT00497198

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Phase 3

Terminated

Conditions: Chronic Kidney Disease
Dialysis
Hyperphosphatemia

Interventions: Drug: Placebo
Drug: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)

First Posted Date: 2007-03-23

Last Posted Date: 2011-11-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 6

Registration Number: NCT00451295

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: Placebo of MCI-186
Drug: MCI-186

First Posted Date: 2007-01-19

Last Posted Date: 2018-08-23

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 181

Registration Number: NCT00424463

Locations: 🇯🇵
National Hospital Organization Miyagi National Hospital, Watari-gun, Miyagi-ken, Japan

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

Phase 3

Completed

Conditions: Hyperphosphatemia
Chronic Kidney Disease

Interventions: Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Drug: Placebo
Drug: Another phosphate binder (Sevelamer)

First Posted Date: 2006-12-28

Last Posted Date: 2014-11-04

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 336

Registration Number: NCT00416520

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: MCI-186
Drug: Placebo of MCI-186

First Posted Date: 2006-12-25

Last Posted Date: 2017-12-20

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 25

Registration Number: NCT00415519

Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: Alteplase

First Posted Date: 2006-12-19

Last Posted Date: 2018-01-19

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 58

Registration Number: NCT00412867

Locations: 🇯🇵
Investigational site 01, Hokkaido, Japan

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: MCI-186
Drug: Placebo of MCI-186

First Posted Date: 2006-05-29

Last Posted Date: 2017-05-17

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 206

Registration Number: NCT00330681

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy